Αn in situ gamma-spectrometry system for the characterization of non-conventional radionuclides for medical research.

The MEDICIS (Medical Isotopes Collected from ISOLDE) facility is a new and unique facility located at CERN (Switzerland) dedicated to the production of non-conventional radionuclides for research and development in imaging, diagnostics and radiation therapy, with very high specific activity. CERN-MEDICIS has been commissioned in September 2017 and delivered its first radionuclides in December 2017. Since then, the facility is shipping novel radioisotopes for medical research to hospitals and scientific institutes in Switzerland and across Europe, which are part of the MEDICIS collaboration. Since its commissioning, the CERN-MEDICIS facility has shown the feasibility of providing radionuclides such as Tb-149, Tb-155, Er-169 and Yb-175 for innovative medical research. For that purpose, the facility used either the 1.4 GeV proton beam coming from the Proton Synchrotron Booster that irradiates the target in ISOLDE hall, a CERN nuclear physics facility, or sources provided by external institutes being part of the MEDICIS collaboration. The radionuclide of interest is extracted through mass separation and implanted on a thin metallic foil. The goal of this master thesis is first to characterize a GR-1 CZT detector from KROMEK with certified sources. The main objective of this project is then to assess the feasibility of using this kind of detector to get an on-line measurement of the activity being implanted on the collection foil. These measurements are complemented with simulations using PENELOPE Monte Carlo code system. Furthermore, other kinds of CZT detectors provided by the Complutense University of Madrid are also characterized in order to compare their capabilities with the ones of the GR-1 CZT detector.